Sarepta Therapeutics

shadow crowd crowded people walking

Biotech

Sarepta's next DMD drug seems to get the job done in phase 2

Sarepta's next Duchenne muscular dystrophy med seems to be doing the job of spurring dystrophin expression. But does it matter given prior approvals?

Annalee Armstrong Jan 29, 2024 10:49am

Peter Marks

FDA's Marks overrules staff drug reviewers 'with trepidation'

Jul 27, 2023 3:05pm

Graphic image of the US from space during the night with lights shining across the country

Santhera offloads North American rights for DMD med to Catalyst

Jun 20, 2023 9:53am

clock time delay cancelled month year hour

FDA needs more time for Sarepta's DMD gene therapy

May 24, 2023 8:39am

green light go go ahead advance yes streetlight

FDA advisers narrowly support Sarepta's DMD gene therapy

May 12, 2023 7:09pm

microphone conference speaker audience

FDA questions benefits, risks of Sarepta DMD gene therapy

May 10, 2023 11:02am